Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AstraZeneca's Imfinzi Plus Chemotherapy Doubled Overall Survival Rate At Three Years For Patients With Advanced Biliary Tract Cancer In TOPAZ-1 Phase 3 Trial

Author: Benzinga Newsdesk | April 16, 2024 05:22am

At more than three years (median follow-up of 41.3 months), results showed Imfinzi plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone. The median OS was 12.9 months for Imfinzi plus chemotherapy versus 11.3 months for chemotherapy alone.

More than twice as many patients on the Imfinzi-based regimen were alive at three years versus chemotherapy alone (14.6% versus 6.9%).

Posted In: AZN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist